Pfizer said that its vaccine candidate has shown more than 90% efficacy in preventing COVID-19 among participants who had not previously been infected with SARS-CoV-2 in the first interim efficacy analysis.
Jay Hartenbach, CEO of Medterra, told Drug Store News in an interview that his company maintains its leadership position by addressing specific consumer needs.